MPDL3280A Breakthrough therapy for ALK resistance

Anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA as a potential treatment for patients with PD-L1–positive non–small cell lung cancer (NSCLC) who have progressed on platinum-based chemotherapy and a EGFR or ALK inhibitor. MPDL3280A is developed by Roche. IV infusion every 3 weeks.

See more at: http://www.targetedonc.com/articles/PD-L1-Inhibitor-MPDL3280A-Receives-Breakthrough-Therapy-Designation-in-NSCLC#sthash.IRSfhKJW.dpuf

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply